CYBIN INC. (HELP)

Pharmaceutical Preparations · market cap $954M · as of 2026-08-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Cybin Inc. (HELP) is a clinical-stage psychedelic/neuropsychiatry pharma with ~50 employees and a $242M market cap trading near $11.45. Its lead asset CYB003 is in Phase 3 for Major Depressive Disorder (MDD), with a secondary program CYB004 in Phase 2 for Generalized Anxiety Disorder. A Phase 3-related catalyst is flagged in our calendar for 2026-12-31.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10
2026-12-31Phase 3imp 7/10

Pipeline

Asset	Phase	Indication
CYB003	Phase 3	Major Depressive Disorder
CYB004	Phase 2	Generalized Anxiety Disorder

Price & technical context

3-month

+99.3%

6-month

+129.3%

12-month

+96.3%

52-wk range

$3.87–$14.02

vs 50-day MA

+0.7%

vs 200-day MA

+58.5%

Realized vol

87.5%

Max drawdown

-67.7%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for HELP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.